AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6133481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 6133481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg and 50 mg
Number of subjects: 94
Study 31082669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Radium-223 55 kBq/kg every six weeks × 5 doses plus docetaxel 60 mg/m2 q3w × 10 doses)
Number of subjects: 53
Study 31082669 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (75 mg/m2 every 3 weeks)
Number of subjects: 53
Study 29605498 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-decision group (surgery assessment at 14 weeks)
Number of subjects: 119
Study 29605498 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group (surgery assessment at 8 weeks)
Number of subjects: 119
Study 29605498 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-decision group
Number of subjects: 119
Study 29605498 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 119
Study 27037563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision tension-free vaginal tape (Ajust™)
Number of subjects: 100
Study 27037563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 100
Study 27037563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 25213339 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 24
Study 22267599 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (Azi) 250 mg/day
Number of subjects: 19
Study 22267599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20123314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing (RAP) therapy
Number of subjects: 0
Study 20123314 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18347115 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight technique
Number of subjects: 10
Study 18347115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism method
Number of subjects: 10
Study 18347115 — intervention group
Group type: COMPARATOR
Intervention: Water volumetry
Number of subjects: 10
Study 18347115 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 10
Study 15833782 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine-morphine mixture (4.8:1 ratio)
Number of subjects: 112
Study 15833782 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine-morphine mixture (1.2:1 ratio)
Number of subjects: 112
Study 12202647 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-ppm fluoride dentifrice
Number of subjects: 0
Study 12202647 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500-ppm fluoride dentifrice
Number of subjects: 0
Study 12202647 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional increment analysis (CVA & FOTI at D(3) threshold + radiography)
Number of subjects: 0
Study 10595609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 41
Study 10595609 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 41
Study 8607681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 8607681 — intervention group
Group type: COMPARATOR
Intervention: No Aprotinin (Control)
Number of subjects: 0
Study 1875405 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supported maintenance condition
Number of subjects: 32
Study 1875405 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact maintenance condition (Control)
Number of subjects: 32
Study 31446213 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib monotherapy (300 mg twice daily)
Number of subjects: 0
Study 31446213 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy treatment of physician's choice (TPC)
Number of subjects: 0
Study 31446213 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 29465210 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol included in infusion therapy before anesthesia
Number of subjects: 48
Study 29465210 — intervention group
Group type: COMPARATOR
Intervention: Control group without antihypoxants
Number of subjects: 48
Study 26072359 — intervention group
Group type: EXPERIMENTAL
Intervention: Worth the Walk intervention (hour-long sessions twice weekly for four weeks)
Number of subjects: 240
Study 26072359 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no immediate intervention)
Number of subjects: 240
Study 23208880 — intervention group
Group type: EXPERIMENTAL
Intervention: YF vaccine and Ig
Number of subjects: 80
Study 23208880 — intervention group
Group type: COMPARATOR
Intervention: YF vaccine and saline placebo
Number of subjects: 80
Study 21802442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg) during atomoxetine maintenance (80 mg/day)
Number of subjects: 7
Study 21802442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine during atomoxetine maintenance (80 mg/day)
Number of subjects: 7
Study 19608354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion combined with cognitive behavioral therapy and contingency management
Number of subjects: 60
Study 17051359 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 2643
Study 17051359 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2643
Study 15139054 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 100
Study 15139054 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel
Number of subjects: 100
Study 15139054 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (30 mg/m2 weekly for 6 weeks)
Number of subjects: 100
Study 11323146 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure feedback
Number of subjects: 76
Study 11323146 — intervention group
Group type: COMPARATOR
Intervention: Success feedback
Number of subjects: 76
Study 11323146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related fear
Number of subjects: 76
Study 11323146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-lifting pain
Number of subjects: 76
Study 9135354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 80
Study 9135354 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and nitrous oxide
Number of subjects: 80
Study 7896588 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 9
Study 7896588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3583091 — intervention group
Group type: EXPERIMENTAL
Intervention: DA agonists (DA, L-dopa, L-dopa plus carbidopa, nomifensine, amphetamine)
Number of subjects: 6
Study 3583091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3583091 — intervention group
Group type: EXPERIMENTAL
Intervention: DA and amphetamine
Number of subjects: 6
Study 31034255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented education (POE)
Number of subjects: 60
Study 31034255 — intervention group
Group type: COMPARATOR
Intervention: Patient-oriented education (POE) and visual aid intervention (wrist band)
Number of subjects: 60
Study 31034255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (POE and WB)
Number of subjects: 60
Study 28422514 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study 28422514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25640832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention (10 years of treatment with various services)
Number of subjects: 891
Study 25640832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 891
Study 25640832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891
Study 23131462 — intervention group
Group type: COMPARATOR
Intervention: 2000 IU/d vitamin D
Number of subjects: 257
Study 23131462 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D
Number of subjects: 257
Study 21455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular continuous peripheral nerve block
Number of subjects: 60
Study 21455085 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular continuous peripheral nerve block
Number of subjects: 60
Study 19660594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 19660594 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT)
Number of subjects: 0
Study 16819382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve supplementation
Number of subjects: 19
Study 16819382 — intervention group
Group type: COMPARATOR
Intervention: Control (without supplementation)
Number of subjects: 19
Study 15769695 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin Management Test (HMT)
Number of subjects: 38
Study 15769695 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Coagulation Time (ACT)
Number of subjects: 38
Study 11116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 microg/kg orally 60 min before surgery)
Number of subjects: 74
Study 11116238 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine premedication)
Number of subjects: 74
Study 9399319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐Hz pure tone
Number of subjects: 30
Study 9399319 — intervention group
Group type: EXPERIMENTAL
Intervention: narrow band noise (700‐1300 Hz band width)
Number of subjects: 30
Study 9399319 — intervention group
Group type: EXPERIMENTAL
Intervention: broad band noise (100‐10,000 Hz band width)
Number of subjects: 30
Study 9399319 — intervention group
Group type: EXPERIMENTAL
Intervention: rock music
Number of subjects: 30
Study 9399319 — intervention group
Group type: EXPERIMENTAL
Intervention: babble speech
Number of subjects: 30
Study 8395557 — intervention group
Group type: EXPERIMENTAL
Intervention: PVnRT‐PCR
Number of subjects: 159
Study 8395557 — intervention group
Group type: COMPARATOR
Intervention: Cell culture and serology
Number of subjects: 159
Study 2941141 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG)
Number of subjects: 220
Study 2941141 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study 31393573 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-treated patients with elevated Lp(a)
Number of subjects: 29
Study 31393573 — intervention group
Group type: COMPARATOR
Intervention: Statin-treated patients with normal Lp(a)
Number of subjects: 29
Study 31393573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 27760084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua sha therapy plus conventional treatment for 8 weeks
Number of subjects: 80
Study 27760084 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 80
Study 27760084 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional treatment alone)
Number of subjects: 80
Study 25925031 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia with dexmedetomidine, lidocaine, and propofol infusions (Group DL)
Number of subjects: 80
Study 25925031 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anesthesia with remifentanil and propofol infusions (Group RF)
Number of subjects: 80
Study 23921331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 6 lumbar facet joints with triamcinolone hexacetonide
Number of subjects: 60
Study 23921331 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of triamcinolone acetonide at 6 lumbar paravertebral points
Number of subjects: 60
Study 21600658 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications
Number of subjects: 607
Study 21600658 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 607
Study 19384786 — intervention group
Group type: EXPERIMENTAL
Intervention: Avastin (1.25 mg in 0.05 mL) every six weeks
Number of subjects: 672
Study 19384786 — intervention group
Group type: COMPARATOR
Intervention: Lucentis (0.05 mg in 0.05 mL) every four weeks
Number of subjects: 672
Study 17040419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligning prism of 2Delta and above for exophoria
Number of subjects: 80
Study 17040419 — intervention group
Group type: COMPARATOR
Intervention: Control lens
Number of subjects: 80
Study 15286056 — intervention group
Group type: COMPARATOR
Intervention: Topical NSAIDs
Number of subjects: 0
Study 11431744 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN-alpha2b 3 times a week plus ribavirin 1,000 mg/d for 12 months
Number of subjects: 594
Study 11431744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN-alpha2b 3 times a week plus ribavirin for 12 months
Number of subjects: 594
Study 11431744 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN-alpha2b 3 times a week plus ribavirin for 6 months
Number of subjects: 594
Study 11431744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN-alpha2b 3 times a week plus ribavirin for 6 months
Number of subjects: 594
Study 11431744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 594
Study 9716146 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV‐C/HGV infection
Number of subjects: 91
Study 9716146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence analysis of GBV‐C/HGV isolates
Number of subjects: 91
Study 9716146 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis
Number of subjects: 91
Study 18415455 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 mug/kg
Number of subjects: 40
Study 18415455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2930802 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensation seekers in the first run showed a tendency toward steeper slopes of the amplitude/stimulus intensity function (ASF).
Number of subjects: 33
Study 2930802 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensation seekers showed an influence of retesting on the slope of the ASF, leading to a decrease of the slope in the second run compared to the first run.
Number of subjects: 33
Study 2930802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sensation seekers showed longer N1 latencies over the right hemisphere than over the left hemisphere.
Number of subjects: 33
Study 790129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclan (Fludilat) administered intravenously at a dosage of 500 mg per day
Number of subjects: 50
Study 790129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 30545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental treatment (pre‐procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2‐day post‐procedural oral cephalexin)
Number of subjects: 12842
Study 30545448 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (pre‐procedural cefazolin infusion)
Number of subjects: 12842
Study 30545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental treatment
Number of subjects: 12842
Study 30545448 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 12842
Study 28550021 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 148
Study 28550021 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 148
Study 26232540 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPV vaccination
Number of subjects: 194
Study 24124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (12 weeks, twice weekly, cardiovascular and strength training, relaxation)
Number of subjects: 216
Study 20869141 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 54
Study 20869141 — intervention group
Group type: COMPARATOR
Intervention: Sham-exercise program
Number of subjects: 54
Study 18533154 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17699351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35 degrees C (HD(35))
Number of subjects: 10
Study 17699351 — intervention group
Group type: COMPARATOR
Intervention: Dialysate temperature at 37 degrees C (HD(37))
Number of subjects: 10
Study 12664788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesacol
Number of subjects: 0
Study 12664788 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 0
Study 10953842 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone nasal drops
Number of subjects: 0
Study 10953842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9169966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 12
Study 9169966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 12
Study 9169966 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 12
Study 9169966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8467286 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF plus rHuEPO
Number of subjects: 18
Study 8467286 — intervention group
Group type: COMPARATOR
Intervention: rhGM‐CSF alone (historical control)
Number of subjects: 18
Study 8467286 — intervention group
Group type: COMPARATOR
Intervention: rhGM‐CSF alone (concurrent control)
Number of subjects: 18
Study 3938925 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate treatment (MIT)
Number of subjects: 399
Study 3938925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MIP)
Number of subjects: 399
Study 30975376 — intervention group
Group type: EXPERIMENTAL
Intervention: Online dietary tool
Number of subjects: 898
Study 30975376 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting ≥2 goals and engaging in self-monitoring
Number of subjects: 898
Study 30975376 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting ≥2 goals
Number of subjects: 898
Study 29068772 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware program
Number of subjects: 184
Study 27310942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental effort training (MET) with low-intensity physical exercise (30% MVC) for 12 weeks
Number of subjects: 27
Study 27310942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional strength training (CST) with high-intensity muscle contractions for 12 weeks
Number of subjects: 27
Study 27310942 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL) with no training
Number of subjects: 27
Study 25139716 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive reduction and percutaneous fixation (MIRPF)
Number of subjects: 45
Study 25139716 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 45
Study 23818202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 200
Study 23818202 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training alone
Number of subjects: 200
Study 21078465 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT (Screening, Brief Intervention, and Referral to Treatment) by emergency nurses
Number of subjects: 0
Study 21078465 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 18256325 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (9 million units/m²/day for 4 days followed 5 days later by 1.6 million units/m²/day for 10 days)
Number of subjects: 376
Study 18256325 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 376
Study 16863482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, without food (treatment A)
Number of subjects: 12
Study 16863482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, with food (treatment B)
Number of subjects: 12
Study 16863482 — intervention group
Group type: COMPARATOR
Intervention: Food alone (treatment C, control)
Number of subjects: 12
Study 14644860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (5 mg twice a day)
Number of subjects: 29
Study 14644860 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 29
Study 14644860 — intervention group
Group type: COMPARATOR
Intervention: Inferior puncta occlusion
Number of subjects: 29
Study 11007680 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/wk of intravenous iron dextran (IVID) for 5 weeks
Number of subjects: 22
Study 11007680 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/wk of intravenous iron dextran (IVID) for 2 weeks
Number of subjects: 22
Study 8820449 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 8
Study 1728443 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Number of subjects: 10
Study 1728443 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Number of subjects: 10
Study 2877386 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg a day)
Number of subjects: 0
Study 2877386 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg a day)
Number of subjects: 0
Study 2877386 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2877386 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 29546560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision (Ta-TME)
Number of subjects: 116
Study 29546560 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic low anterior resection (L-LAR)
Number of subjects: 116